Nevro to Report First Quarter 2021 Financial Results

Rhea-AI Summary

Nevro Corp. (NYSE: NVRO) will report its financial results for Q1 2021 after the market closes on May 5, 2021. A conference call is scheduled for the same day at 1:30 PM PT to discuss the results. Investors can join the call by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally. Nevro focuses on innovative solutions for chronic pain, with its Senza spinal cord stimulation system showing the potential to reduce opioid use in over 65% of patients. For more information, visit www.nevro.com.

Positive

• Senza system demonstrated efficacy in reducing opioid use in ≥65% of patients across multiple clinical studies.

Negative

• None.

REDWOOD CITY, Calif., April 7, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021.

Management will host a conference call on May 5, 2021 to discuss first quarter 2021 financial results. The call will begin at 1:30 pm PT/ 4:30 pm ET.  Investors interested in listening to the call may do so by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally, using Conference ID: 6194499. A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com. 

Internet Posting of Information

Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com.  The company encourages investors and potential investors to consult the Nevro website regularly for important information about Nevro.

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in ≥65% of patients across six peer-reviewed clinical studies. The Senza^® System, Senza II™ System, and the Senza^® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10^® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.

To learn more about Nevro, connect with us on LinkedIn, Twitter, Facebook and Instagram.

Investors and Media:
Julie Dewey, IRC
Nevro Corp.
Vice President, Investor Relations & Corp Communications
650-433-3247  |  julie.dewey@nevro.com

 

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/nevro-to-report-first-quarter-2021-financial-results-301248063.html

SOURCE Nevro Corp.

FAQ

When will Nevro report its Q1 2021 financial results?

Nevro will report its Q1 2021 financial results after the market closes on May 5, 2021.

What is the conference call schedule for Nevro's Q1 2021 results?

The conference call will be held on May 5, 2021, at 1:30 PM PT.

How can investors access Nevro's financial results conference call?

Investors can access the conference call by dialing (833) 968-2321 in the U.S. or +1 (778) 560-2840 internationally.

What is the significance of Nevro's Senza spinal cord stimulation system?

The Senza system has shown the ability to reduce or eliminate opioids in over 65% of patients according to clinical studies.